A dominant topic for the ASRS Research and Safety in Therapeutics committee has been brolucizumab-related issues, particularly the risk for occlusive vasculitis and vision loss following treatment for neovascular AMD.
“Brolucizumab was approved in October 2019, and shortly thereafter the ReST committee started receiving reports of inflammation,” including intraocular inflammation (IOI) with and without vasculitis, said Paul Hahn, MD, PhD, who moderated a panel on drug safety at the virtual American Society of Retina Specialists meeting.
Beovu (brolucizumab, Novartis) is the newest
Uncategorized